Biliary Tract Cancer

Patients with advanced biliary tract cancer can safely use antibiotics while benefiting from treatment with durvalumab plus gemcitabine and cisplatin, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Healio presents the following collection of FDA news related to gastroenterology, including the approval of generic diarrhea relief tablets, treatment for acid sphingomyelinase deficiency and biliary tract cancer, and more.

Cristina R. Ferrone, MD, has been appointed chair of the department of surgery at Cedars-Sinai.

The FDA approved durvalumab with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer.

Gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, produced favorable outcomes as first-line treatment for advanced biliary tract cancer, according to research.

The FDA granted priority review to durvalumab plus chemotherapy for treatment of locally advanced or metastatic biliary tract cancer.

A phase 3 study of acelarin in combination with cisplatin for biliary tract cancer is being discontinued at the recommendation of the study’s independent data monitoring committee, according to a press release from the agent’s manufacturer.

The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.

Adjuvant S-1 therapy significantly extended survival compared with surgery alone among patients with resected biliary tract cancer, according to results of a study conducted in Japan and presented at ASCO Gastrointestinal Cancers Symposium.

The addition of durvalumab to gemcitabine and cisplatin significantly extended OS among patients with advanced biliary tract cancer, according to results of a phase 3 study scheduled for presentation at ASCO Gastrointestinal Cancers Symposium.